Rakovina Therapeutics Inc Total Liabilities
Rakovina Therapeutics Inc total liabilities. Based on the latest financial reports, Rakovina Therapeutics Inc (RKV) has total liabilities worth CA$3.38 Million CAD (≈ $2.45 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See defensive interval ratio of Rakovina Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Rakovina Therapeutics Inc (2021–2024)
Total liabilities of Rakovina Therapeutics Inc from 2021 to 2024. This chart illustrates how Rakovina Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Rakovina Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Rakovina Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Smooth Rock Ventures Corp
V:SMRV
|
Canada | CA$74.60K |
|
Omega Therapeutics Inc
NASDAQ:OMGA
|
USA | $141.18 Million |
|
Calidi Biotherapeutics Inc.
NYSE MKT:CLDI
|
USA | $5.10 Million |
|
Sylvania Platinum Limited
LSE:SLP
|
UK | GBX51.28 Million |
|
Empire Metals Limited
LSE:EEE
|
UK | GBX377.34K |
|
Lithium Universe Ltd
AU:LU7
|
Australia | AU$2.58 Million |
|
FEEDBACK PLC LS-5
F:GZM0
|
Germany | €400.00K |
Liability Composition Analysis (2021–2024)
This chart breaks down Rakovina Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Rakovina Therapeutics Inc.
Liquidity & Leverage Metrics
Rakovina Therapeutics Inc Total Liabilities Ratios Explained
Rakovina Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rakovina Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rakovina Therapeutics Inc (2021–2024)
The table below shows the annual total liabilities of Rakovina Therapeutics Inc from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$1.94 Million ≈ $1.40 Million |
+30.53% |
| 2023-12-31 | CA$1.49 Million ≈ $1.08 Million |
+1289.79% |
| 2022-12-31 | CA$107.05K ≈ $77.44K |
-6.08% |
| 2021-12-31 | CA$113.98K ≈ $82.45K |
-- |
About Rakovina Therapeutics Inc
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series … Read more